Hepatic Inflammation Articles & Analysis

1 news found

Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

The primary endpoints will be to determine the changes in both intrahepatic lipid content and hepatic inflammation and fibrosis with growth hormone (GH) augmentation as measured by 1H-MRS and Perspectum’s LiverMultiScan®. ...

May 5, 2022

ByLumos Pharma

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you